Dianthus Therapeutics, Inc. /DE/ 8-K

What Happened
Dianthus Therapeutics, Inc. (DNTH) filed an 8‑K on March 9, 2026 announcing two main items: (1) it released financial results for the quarter and full year ended December 31, 2025, and (2) it announced an early "GO" decision following an interim responder analysis in its Phase 3 CAPTIVATE trial of claseprubart for chronic inflammatory demyelinating polyneuropathy (CIDP). The company furnished a press release, a data press release, and a data presentation and held a conference call/webcast the same day at 8:00 a.m. ET to discuss the results.

Key Details

• Date filed: March 9, 2026; conference call/webcast held March 9, 2026 at 8:00 a.m. Eastern Time.
• Clinical program: Early "GO" decision based on an interim responder analysis in the Phase 3 CAPTIVATE trial of claseprubart for CIDP.
• Financial disclosure: Press release announced financial results for the quarter and full year ended December 31, 2025 (details are in the furnished press release).
• Materials furnished: Exhibit 99.1 (press release), Exhibit 99.2 (data press release), Exhibit 99.3 (data presentation) — furnished, not “filed” under Section 18.

Why It Matters
For investors, the filing combines clinical and financial news: the early "GO" decision signals a development milestone for Dianthus’s lead program in CIDP and could affect the timeline or strategic planning for the Phase 3 program. The simultaneous release of quarterly and full‑year results provides updated financial and operational context (earnings, revenue/expense trends, cash position) that investors should review in the furnished press release and presentation. Listen to the company’s webcast or read the exhibits for the detailed interim analysis data and the specific financial figures disclosed.